Actively Recruiting
Study of Plasma and Urinary Biomarkers to Predict Hepatorenal Syndrome in Adults with Advanced Cirrhosis
Led by The University of Hong Kong · Updated on 2024-12-16
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying advanced cirrhosis patients to evaluate novel plasma and urinary biomarkers that may predict the development of hepatorenal syndrome. The study compares patients who have developed hepatorenal syndrome with those who have not, aiming to understand how these biomarkers relate to the condition. It is an observational study sponsored by The University of Hong Kong. The biomarkers being monitored include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1, and urinary LFABP. These biomarkers will be measured and compared between patients with and without hepatorenal syndrome to identify potential indicators of the syndromes occurrence. Participants will be adults aged 18 to 90 with advanced cirrhosis referred for liver transplantation. Researchers will observe and collect biomarker data and monitor the development of hepatorenal syndrome over 12 weeks, with secondary outcomes including mortality and chronic renal impairment over 6 months. The study involves no treatment interventions, focusing on biomarker assessment and patient outcomes during the observation period.
CONDITIONS
Brief Title
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Research Team
D
Desmond Yap, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here